DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation.


File Description SizeFormat
HepRes39_856.pdf182.66 kBAdobe PDFView/Open

Title: Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation.
Authors: Ichikawa, Tatsuki / Nakao, Kazuhiko / Miyaaki, Hisamitsu / Eguchi, Susumu / Takatsuki, Mitsuhisa / Fujimito, Masumi / Akiyama, Motohisa / Miuma, Satoshi / Ozawa, Eisuke / Shibata, Hidetaka / Takeshita, Shigeyuki / Kanematsu, Takashi / Eguchi, Katsumi
Issue Date: Sep-2009
Publisher: Blackwell Publishing Inc.
Citation: Hepatology research, 39(9), pp.856-864; 2009
Abstract: Aim: To identify the problems of pegylated interferon (PEG IFN) with ribavirin therapy against hepatitis C virus (HCV) reinfection in living donor liver transplantation (LDLT) patients. HCV kinetics during the PEG IFN with ribavirin therapy were analyzed in LDLT patients, as well as in chronic hepatitis C (CHC) patients. Methods: The study included 80 consecutive HCV infected patients undergoing PEG IFN with ribavirin therapy (64 CHC and 16 LDLT patients) who attended the Nagasaki University Hospital for an initial visit between January 2005 and December 2007. Results: The sustained viral response (VR) rate of the CHC group (80%) was superior to the LDLT group (22%). The viral disappearance rate of the CHC group was also superior to the LDLT group, regardless of the HCV serotype. The HCV core antigen (cAg) titer under treatment in the LDLT group was more than that of the CHC group from day 0 to week 12. The HCV cAg decrease rate of the LDLT group on the first day of treatment was less than that of the CHC group. Conclusion: The HCV infection of a transplanted liver is more refractory to treatment than a non-transplanted liver. The low reduction HCV cAg rate on day 1 is one of the problems of the combination therapy.
Keywords: Chronic hepatitis C / First phase / Hepatitis C virus / Interferon / Living donor liver transplantation
URI: http://hdl.handle.net/10069/24038
ISSN: 13866346
DOI: 10.1111/j.1872-034X.2009.00524.x
PubMed ID: 19624776
Rights: © 2009 The Japan Society of Hepatology / This is the author's version of the work. It is posted here by permission of The Japan Society of Hepatology for personal use, not for redistribution. The definitive version was published in Hepatology Research, Volume 39, Issue 9, Pages 856-864. http://dx.doi.org/10.1111/j.1872-034X.2009.00524.x
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/24038

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace